SANDOGLOBULIN trademark

SANDOGLOBULIN - Trademark Information

Trademark by SANDOZ PHARMACEUTICALS CORPORATION

The SANDOGLOBULIN trademark was assigned a Serial Number #73394127 – by the United States Patent and Trademark Office (USPTO). Trademark Serial Number is a unique ID to identify the SANDOGLOBULIN mark in USPTO. The SANDOGLOBULIN mark is filed in the category of Pharmaceuticals. The legal correspondent for SANDOGLOBULIN trademark is MAURY M TEPPER III, WOMBLE CARLYLE SANDRIDGE & RICE PLLC, PO BOX 831, RALEIGH, NORTH CAROLINA UNITED STATES 27602 . The current status of the SANDOGLOBULIN filing is Registration cancelled because registrant did not file an acceptable declaration under Section 8..

Based on SANDOZ PHARMACEUTICALS CORPORATION, the SANDOGLOBULIN trademark is used in the following business: Medicinal Preparation Used as an Antibody Supplement.

LegalHoop is the largest free online trademark search, trademark monitoring, and tracking platform. We provide online software to streamline the process, helping clients do trademark & patent searches, applications, and monitoring more automatically and efficiently. You can create a free account on LegalHoop.com and monitor all of your trademarks from one convenient dashboard, and receive free status updates any time when the status is changed.

Have a Name, Slogan, or Logo to protect? LegalHoop, an Experienced IP Agent Made It Easy - Trademark Registration in 200 Countries.

Set up your brands for success! The United States is the most difficult country in the world to register a trademark. The trademark process in the United States takes approximately one year and is fraught with pitfalls. Approximately 60% of all applications receive a refusal. Many of these refusals can be overcome by strategic work of an experienced IP consultant, but DIY-applications generally are NOT successful.

We have extensive expertise in intellectual property law, including but not limited to trademark, copyright, and patent matters in multiple countries. You can count on our vast experience in filing trademark applications and trademark maintenance to help get your trademark protected properly, cost-effectively and efficiently.

Select the Filing Country:

Trademark Registration in USA

$199

$199 + Govt Fee* (1 class)

STANDARD PACKAGE

Basic Direct-Hit Searchto help avoid obvious duplications of pre-existing marks.
Professional Preparationof your trademark application.
Electronic Deliveryof your trademark application with no need to wait for mail or dealing with paper files. This will qualify you the reduced government filing fee.
Free Search & Evaluation on Alternative Mark if Your Attorney Thinks There's an Issue with Your First Choice.

* The Trademark government fee will be charged when we submit your mark(s) to the Government Trademark Office, which is usually in the next few business days.

SERIAL NUMBER
73394127
WORD MARK
SANDOGLOBULIN
CURRENT STATUS
Registration cancelled because registrant did not file an acceptable declaration under Section 8.
STATUS DATE
Sunday, November 07, 2004
FILING DATE
Wednesday, September 29, 1982
PRIORITY-CLAIM INTERNATIONAL FILING DEADLINE:

March 29, 1983
(PRIORITY CLAIM MUST BE FILED WITHIN SIX MONTHS OF FOREIGN FILING)
Trademarks are territorial. US trademark registration will not protect your trademark in a foreign country. If you have plan to protect your trademark internationally, see more options below :
REGISTRATION NUMBER
1265559
REGISTER TYPE
Principal
TRADEMARK OWNER
59 ROUTE 10, EAST HANOVER, NEW JERSEY UNITED STATES 07936
Owner Type: CORPORATION
TRADEMARK CORRESPONDENT
WOMBLE CARLYLE SANDRIDGE & RICE PLLC, PO BOX 831, RALEIGH, NORTH CAROLINA UNITED STATES 27602
Trademark Classification Information
CLASS INFO
Class 005 - Pharmaceuticals

First Use Anywhere:
First Use in Commerce:
Trademark Goods and Services Description
DESCRIPTION
Class 005 - Medicinal Preparation Used as an Antibody Supplement

Start Trademark Search

Search Now

Current Status:

Registration cancelled because registrant did not file an acceptable declaration under Section 8.

11/7/2004